incidence of FNP, complication rates and mortality
Despite relatively high rates of low neutrophil counts during standard dose chemotherapy regimens for malignancies other than acute leukemias, rates of FNP, other complication rates and mortality rates are relatively low for most standard chemotherapies (Table 1) .
These rates do not justify the use of hematopoietic growth factors (hGFs) such as granulocyte colony-stimulating factor (G-CSF) or its pegylated form (pegfilgrastim). Colonystimulating growth factors should not be used in patients without neutropenia and especially not in patients suffering from community-or hospital-acquired pneumonitis [I, A].
indication for primary prophylaxis of FNP by hGFs Table 2 describes the indications for primary prophylaxis of  FNP by hGFs and Table 3 gives examples of chemotherapy regimens with a risk of FNB of 20%.
special situations for use of hGFs for standard therapy Risk for severe thrombocytopenia when hGFs are given immediately before or simultaneously with chemotherapy.
Possible risk of subsequent acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in women receiving adjuvant chemotherapy for breast cancer and hGFs. Even if these results will be confirmed, the absolute risk is low (1.8% versus 0.7% use of G-CSF and pegfilgrastim in highrisk situations
Therapy of acute leukemias, autologous and allogeneic stem cell transplantations (TPLs) lead to higher risks of FNP and potentially lethal complications.
Incidence of FNP in high-risk situations: regular during autologous and allogeneic peripheral blood stem-cell (PBSC)-TPLs and bone marrow TPL, during graft failure, in 35-48% of AML cases at diagnosis, and in 13-30% during acute lymphoblastic leukemia (ALL) induction chemotherapy.
Mortality: 0-10% in autologous TPL, highly variable in allogeneic TPL, 80% during graft failure, 20-26% during first 2 months in AML and 2-10% during induction of ALL.
indications for granulopoietic CSFs in high-risk situations 
G-CSF after autologous stem-cell TPL

special comments on CSFs as a treatment for radiation injury
Lethal doses of total body radiotherapy (accidental or intentional). 
